Effectiveness of sulfasalazine and methotrexate in 1102 DMARD-naïve patients with early RA

Rheumatology

Volumn 51, Issue 4, 2012, Pages 670-678

  Lie, Elisabeth ^a   Uhlig, Till ^a   Van der heijde, Désirée ^a,b   Rødevand, Erik ^c   Kalstad, Synøve ^d   Kaufmann, Cecilie ^e   Mikkelsen, Knut ^f   Kvien, Tore K ^a  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^e Buskerud Central Hospital   (Norway)

^f Hospital for Rheumatic Diseases   (Norway)

Author keywords

Methotrexate; Rheumatoid arthritis; Sulfasalazine

Indexed keywords

METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG WITHDRAWAL; EARLY INTERVENTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPENSITY SCORE; REMISSION; RHEUMATOID ARTHRITIS; SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DRUG EVALUATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; METHOTREXATE; MIDDLE AGED; REMISSION INDUCTION; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX; SULFASALAZINE; TREATMENT OUTCOME;

EID: 84858633536     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker356     Document Type: Article

References (43)

1. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
2. Quinn MA, Conaghan PG, Emery P. The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence? Rheumatology 2001;40:1211-20.
3. Suarez-Almazor ME, Belseck E, Shea B et al. Sulfasalazine for rheumatoid arthritis. Cochrane Database Syst Rev 2000;2:CD000958.
4. Suarez-Almazor ME, Belseck E, Shea B et al. Methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000;2:CD000957.
5. Gaujoux-Viala C, Smolen JS, Landewe R et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:1004-9.
6. Haagsma CJ, van Riel PL, de Jong AJ et al. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997;36:1082-8.
7. Dougados M, Combe B, Cantagrel A et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999;58:220-5.
8. Hider SL, Silman A, Bunn D et al. Comparing the long-term clinical outcome of treatment with methotrexate or sulfasalazine prescribed as the first disease-modifying antirheumatic drug in patients with inflammatory polyarthritis. Ann Rheum Dis 2006;65:1449-55.
9. Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology 2002;41: 1367-74.
10. Sokka T. Increases in use of methotrexate since the 1980s. Clin Exp Rheumatol 2010;28:S13-20.
11. Welsing PM, Fransen J, van Riel PL. Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis. Arthritis Rheum 2005;52:2616-24.
12. Saag KG, Teng GG, Patkar NM et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59: 762-84.
13. Pincus T, Summey JA, Soraci SA Jr et al. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;26:1346-53.
14. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
15. Loge JH, Kaasa S, Hjermstad MJ et al. Translation and performance of the Norwegian SF-36 Health Survey in patients with rheumatoid arthritis. I. Data quality, scaling assumptions, reliability, and construct validity. J Clin Epidemiol 1998;51:1069-76.
16. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92.
17. Prevoo ML, van't Hof MA, Kuper HH et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
18. Smolen JS, Breedveld FC, Schiff MH et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003;42: 244-57.
19. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
20. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
21. Felson DT, Smolen JS, Wells G et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63:573-86.
22. Felson DT, Smolen JS, Wells G et al. American college of rheumatology/european league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13.
23. Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006;54:600-6.
24. Wiles NJ, Lunt M, Barrett EM et al. Reduced disability at five years with early treatment of inflammatory polyarthritis: results from a large observational cohort, using propensity models to adjust for disease severity. Arthritis Rheum 2001;44:1033-42.
25. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17: 2265-81.
26. Choi HK, Hernan MA, Seeger JD et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7.
27. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2005;54:26-37.
28. Klareskog L, van der HD, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
29. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
30. Maini RN, Taylor PC, Szechinski J et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29.
31. Aletaha D, Stamm T, Kapral T et al. Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis 2003;62:944-51.
32. Maetzel A, Wong A, Strand V et al. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology 2000;39:975-81.
33. Papadopoulos NG, Alamanos Y, Papadopoulos IA et al. Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study. J Rheumatol 2002;29:261-6.
34. Smolen JS, Aletaha D, Bijlsma JW et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
35. Rachapalli SM, Williams R, Walsh DA et al. First-line DMARD choice in early rheumatoid arthritis-do prognostic factors play a role? Rheumatology 2010;49:1267-71.
36. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
37. Aletaha D, Neogi T, Silman AJ et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
38. Visser K, Katchamart W, Loza E et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68: 1086-93.
39. Boers M. Missing data in trials: do we have to keep carrying the last observation forward? Arthritis Rheum 2008; 59:2-3.
40. Smolen JS, Kalden JR, Scott DL et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999;353:259-66.
41. Choy EH, Scott DL, Kingsley GH et al. Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage: a randomised double blind trial of sulphasalazine vs diclofenac sodium. Clin Exp Rheumatol 2002;20:351-8.
42. Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999;159: 2542-50.
43. Pincus T, Ferraccioli G, Sokka T et al. Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology 2002;41:1346-56.